Infantile Spasms in Tuberous Sclerosis: First-Line Treatment

This protocol addresses infantile spasms in a patient with tuberous sclerosis — a clinically distinct setting in which the underlying aetiology directly shapes therapy selection and expected response.

Clinical Setting

Tuberous sclerosis is a specific, identifiable cause of infantile spasms that calls for a targeted first-line approach. Patients with this diagnosis respond differently to available therapies compared with patients without an identified aetiology, and this distinction is reflected in current evidence-based recommendations.

Treatment Approach

There is a well-established preferred first-line antiepileptic agent for infantile spasms in the setting of tuberous sclerosis, with a defined treatment duration guided by clinical response. The complete structured regimen — including dosing, monitoring, duration, and tapering criteria — is available in the full protocol.

Clinical Goals

Successful treatment is defined by complete cessation of spasms and resolution of hypsarrhythmia on video EEG. When therapy is effective, response is typically observed within two weeks of initiation.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3978/j.issn.2224-4336.2015.09.01

Patients with tuberous sclerosis are more likely to respond to treatment with vigabatrin, whereas patients without an identified etiology may respond better to hormonal therapy.
Vigabatrin is the preferred first-line therapy for patients with infantile spasms and tuberous sclerosis, with some studies showing efficacy of greater than 90% in patients with tuberous sclerosis.
In responders, it is recommended to discontinue therapy after 6 months to limit the chances of peripheral visual field constriction.
It is recommended to stop therapy after 14 days if no response is noted.
The goals of therapy should include a complete cessation of the clinical events and resolution of hypsarrhythmia or modified hypsarrhythmia on video EEG.
Response occurred within 2 weeks of therapy in most patients and not after 12 weeks.

View source ↗